Check all this out! This company has major things going for it! No wonder Sabby Hedge fund took up a major postion in it!
Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients with numerous different tumor types. Inspyr Therapeutics’ team has substantial pharmaceutical industry and scientific experience. The Company lists on the OTC Markets Group’s OTCQB.?
?
Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.?
?
Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). Furthermore, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.?
?
Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program focuses on the treatment of gastric cancer.
Inspyr has commenced a preclinical study in gastric cancer PDX tumor models, which express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.??
?
In addition, the Company plans to evaluate Mipsagargin in combination with DC101 (Cyramza® surrogate antibody). Paclitaxel and Cyramza® are approved for the treatment of gastric cancer.
Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. The innovative platform technology has the potential to work across a range of drugs that precisely target different cancers.??? ??
??
In May 2017, Inspyr Therapeutics and Lewis and Clark Pharmaceuticals announced that they entered into an agreement to create an integrated company with a proprietary platform driving a pipeline of novel therapeutics. With this agreement, Inspyr Therapeutics will purchase Lewis and Clark in an all-stock transaction. Lewis and Clark Pharmaceuticals is a privately-held biotechnology company.
In October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary compounds generated via the Company’s adenosine receptor modulator (ARM) technology platform. The preclinical study will assess adenosine receptor agonists for the management of atherosclerosis.
Furthermore, in October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.
Inspyr Therapeutics has fully-equipped, state-of-the-art organic and analytical chemistry laboratories in Charlottesville, Virginia. At these laboratories, a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.
